CA
NZ
UK
AU
IND
US
…
ViewRay Systems, Inc. designs, manufactures, and markets magnetic resonance imaging radiation therapy system in the United States and internationally. The company offers MRIdian A3i, an MRI-guided radiation therapy system that provides real-time 3D tissue tracking and automated beam control. Its product is used for the treatment of pancreas, prostate, lung, liver, breast, and oligometastatic cancers. The company was founded in 2004 and is headquartered in Oakwood, Ohio. On July 16, 2023, ViewRay, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. On October 26, 2023, the voluntary petition of ViewRay, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on July 16, 2023.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
ViewRay makes MRIdian MRI-guided radiation therapy systems and provides related services and software for cancer treatment. Long-term growth could come from wider clinical adoption of MRI-guided radiotherapy, expansion of the installed base with recurring service and software revenue, and international penetration; the company may appeal to investors seeking exposure to a specialized, technology-driven segment of radiation oncology.
Key risks are intense competition from larger radiotherapy firms, long capital-intensive sales cycles with reimbursement sensitivity, and heightened financing and liquidity risk associated with OTC Pink trading and reduced public disclosure.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -107.33M | -110.05M | -107.91M | -120.20M | -76.40M |
| Net income | -107.33M | -110.05M | -107.91M | -120.20M | -76.40M |
| Selling general administrative | 82.92M | 72.14M | 76.91M | 91.52M | 50.11M |
| Selling and marketing expenses | - | - | - | - | 15.06M |
| Gross profit | 10.04M | 0.34M | -4.06M | -5.48M | 6.60M |
| Reconciled depreciation | 4.92M | 5.98M | 6.42M | 4.66M | - |
| Ebit | -105.31M | -103.65M | -105.98M | -120.80M | -68.76M |
| Ebitda | -102.27M | -105.81M | -104.60M | -115.87M | -65.26M |
| Depreciation and amortization | - | - | - | - | 3.50M |
| Operating income | -105.31M | -103.65M | -105.98M | -120.80M | -75.09M |
| Other operating expenses | - | - | - | - | 156.05M |
| Interest expense | 5.06M | 4.24M | 3.31M | 4.33M | 7.70M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Interest income | 1.69M | 0.01M | 0.79M | 1.72M | - |
| Net interest income | -3.37M | -4.23M | -2.52M | -2.61M | - |
| Total revenue | 102.21M | 70.12M | 57.02M | 87.78M | 80.96M |
| Total operating expenses | 207.52M | 173.77M | 162.99M | 208.58M | 81.69M |
| Cost of revenue | 92.16M | 69.78M | 61.08M | 93.26M | 74.36M |
| Total other income expense net | 1.35M | -2.17M | 0.58M | 3.20M | -1.30M |
| Net income from continuing ops | -107.33M | -110.05M | -107.91M | -120.20M | - |
| Net income applicable to common shares | -107.33M | -110.05M | -107.91M | -120.20M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 271.40M | 321.81M | 261.55M | 350.02M | 294.97M |
| Other current assets | 10.52M | 6.64M | 4.35M | 5.57M | 23.92M |
| Total liab | 189.16M | 152.01M | 131.29M | 133.84M | 127.66M |
| Total stockholder equity | 82.24M | 169.79M | 130.27M | 216.17M | 167.31M |
| Other current liab | 42.40M | 35.80M | 26.95M | 21.18M | 5.58M |
| Common stock | 1.81M | 1.78M | 1.48M | 1.46M | 0.95M |
| Capital stock | 1.81M | 1.78M | 1.48M | 1.46M | - |
| Retained earnings | -844.46M | -737.13M | -627.08M | -519.18M | -398.98M |
| Other liab | 9.03M | 13.67M | 8.39M | 10.30M | - |
| Other assets | 17.42M | 8.31M | 2.89M | 2.98M | - |
| Cash | 135.96M | 218.35M | 156.72M | 226.78M | 167.43M |
| Total current liabilities | 96.58M | 76.24M | 56.91M | 59.07M | 53.89M |
| Current deferred revenue | - | - | - | - | 33.70M |
| Net debt | - | - | - | - | -112.07M |
| Short long term debt | - | 3.22M | - | 1.56M | - |
| Short long term debt total | - | - | - | - | 55.36M |
| Other stockholder equity | - | - | - | - | 565.33M |
| Property plant equipment | 25.59M | 29.90M | 34.19M | 35.12M | - |
| Total current assets | 228.35M | 283.55M | 224.43M | 311.86M | 277.68M |
| Net tangible assets | 82.20M | 169.75M | 130.22M | 216.12M | - |
| Net receivables | 41.38M | 21.66M | 11.77M | 16.82M | 36.87M |
| Long term debt | 78.34M | 54.03M | 56.94M | 53.99M | - |
| Inventory | 38.79M | 34.40M | 48.73M | 61.49M | 49.46M |
| Accounts payable | 28.30M | 9.20M | 9.98M | 13.74M | 13.83M |
| Non currrent assets other | 17.42M | 8.31M | 2.89M | 2.98M | 3.33M |
| Non current assets total | 43.04M | 38.26M | 37.13M | 38.16M | 17.29M |
| Capital lease obligations | 8.06M | 10.63M | 11.13M | 12.74M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -3.90M | -1.56M | -6.18M | -7.82M | - |
| Change to liabilities | 23.27M | 10.06M | 1.10M | -13.01M | - |
| Total cashflows from investing activities | -3.90M | -1.56M | -6.18M | -7.82M | -3.69M |
| Net borrowings | 22.00M | 22.00M | 2.00M | 2.00M | - |
| Total cash from financing activities | 18.29M | 125.28M | -0.35M | 146.21M | 236.71M |
| Change to operating activities | -9.31M | -0.13M | -1.83M | 11.71M | - |
| Net income | -107.33M | -110.05M | -107.91M | -120.20M | -76.40M |
| Change in cash | -77.31M | 61.63M | -70.01M | 58.82M | 110.83M |
| Begin period cash flow | 219.81M | 158.18M | 228.19M | 169.37M | 58.53M |
| End period cash flow | 142.50M | 219.81M | 158.18M | 228.19M | 169.37M |
| Total cash from operating activities | -91.71M | -62.09M | -63.47M | -79.57M | -122.19M |
| Issuance of capital stock | 0.00M | 137.88M | 0.00M | 149.56M | - |
| Depreciation | 5.02M | 6.09M | 6.48M | 4.70M | 3.43M |
| Change to inventory | -4.26M | 12.87M | 12.61M | -4.27M | -32.21M |
| Change to account receivables | -20.03M | -9.89M | 5.05M | 20.05M | -16.54M |
| Other cashflows from financing activities | -1.87M | -9.33M | -1.35M | -10.58M | -6.17M |
| Change to netincome | 19.51M | 28.04M | 20.29M | 20.75M | - |
| Capital expenditures | 3.90M | 1.56M | 6.18M | 7.76M | 3.69M |
| Change in working capital | -10.33M | 12.91M | 16.93M | 14.48M | -60.51M |
| Stock based compensation | 21.61M | 23.87M | 22.80M | 19.45M | 14.17M |
| Other non cash items | 1.02M | 1.91M | 0.94M | 0.75M | -2.96M |
| Free cash flow | -95.61M | -63.65M | -69.66M | -87.38M | -125.88M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| VRAYQ ViewRay Inc. |
- -% |
0.00 | - | - | 0.00 | - | 0.04 |
| ABT Abbott Laboratories |
-0.71 0.65% |
108.58 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 |
| MDT Medtronic PLC |
0.28 0.28% |
101.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 |
| SYK Stryker Corporation |
-2.16 0.68% |
316.63 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 |
| SEMHF Siemens Healthineers AG |
- -% |
47.31 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 |
ViewRay Systems, Inc. designs, manufactures, and markets magnetic resonance imaging radiation therapy system in the United States and internationally. The company offers MRIdian A3i, an MRI-guided radiation therapy system that provides real-time 3D tissue tracking and automated beam control. Its product is used for the treatment of pancreas, prostate, lung, liver, breast, and oligometastatic cancers. The company was founded in 2004 and is headquartered in Oakwood, Ohio. On July 16, 2023, ViewRay, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. On October 26, 2023, the voluntary petition of ViewRay, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on July 16, 2023.
| Name | Title | Year Born |
|---|---|---|
| Mr. Paul Ziegler Jr., J.D. | President, CEO & Director | 1974 |
| Dr. James F. Dempsey Ph.D. | Founder & Chief Scientific Officer | 1971 |
| Mr. Andrew James Hill | Senior Vice President of Operations & Development | 1985 |
| Matt Harrison | Director of Investor Relations | NA |
| Mr. Sanket Shah J.D. | Senior VP & General Counsel | 1983 |
| Ms. Julianne Mast | Vice President of Human Resources | NA |
| Dr. Martin Fuss M.D., Ph.D. | Chief Medical Officer | NA |
| Mr. Adam Podbelski | Senior Vice President of Commercial Operations | NA |
| Mr. Steven Annen | Senior Vice President of Global Marketing | 1964 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...